Floatz logo

Pembrolizumab/Vibostolimab Coformulation

Endometrial Neoplasms

Merck Sharp & Dohme LLCPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Endometrial Neoplasms cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BBB
LENVATINIB
Merck Sharp & Dohme LLC
Phase 3BB
Pembrolizumab
Eli Lilly and Company
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 3BB
Carboplatin
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab/Vibostolimab Coformulation is also rated in:

head and neck squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
gallbladder cancerDormant
B
Indicative ·
57 / 100
View asset →
uterine cervix neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →